43 patents
Utility
Agitation process for preparing a carbetocin drug product
19 Dec 23
The present disclosure includes a method of making an improved carbetocin drug product.
Christopher Bryant, Mark C. Manning, Ryan E. Holcomb
Filed: 2 Mar 22
Utility
Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
12 Dec 23
Marlon Carlos, Sagun Tandel, Roger Olsson, Mikael Hillgren, Matthew J. Fleming, Andreas Philipp Boudier, Beat T. Weber
Filed: 16 Mar 21
Utility
Crystalline forms of trofinetide
28 Nov 23
This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.
Matthew Peterson, Marlon Carlos, Martin Bernard Catherine Bousmanne, Cecilia Betti, David T. Jonaitis, Lisa M. McCracken, Lisa M. Grove
Filed: 12 Jul 22
Utility
Crystalline Forms of Trofinetide
26 Jan 23
This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.
Matthew PETERSON, Marlon CARLOS, Martin Bernard Catherine BOUSMANNE, Cecilia BETTI, David T. JONAITIS, Lisa M. MCCRACKEN, Lisa M. GROVE
Filed: 12 Jul 22
Utility
Methods and Compositions for Treatment of Rett Syndrome
27 Oct 22
Disclosed herein are methods of treating Rett syndrome comprising administering trofinetide to a subject in need thereof in which a dosage is provided that may reduce or avoid underexposure, e.g., in low body weight subjects, and/or provide other benefits.
MONA DARWISH, JAMES M. YOUAKIM, LAWRENCE IRWIN GLASS, NANCY ELIZABETH JONES, SEAN PAUL OOSTERHOLT, OSCAR DELLA PASQUA
Filed: 1 Feb 22
Utility
Pimavanserin for Treating Neurodegenerative Diseases
13 Oct 22
The disclosure provides, in part, a method of treating a disorder in a patient in need of pimavanserin, the method comprising administering to the patient about 2 mg to about 80 mg of pimavanserin via, e.g., an enteral feeding tube, once daily, wherein pimavanserin is dissolved in, mixed with, or sparkled onto, e.g., about 5 mL to about 150 mL of, a liquid vehicle or soft food vehicle at ambient or cold temperature before the administration.
Allan Bokser, Yvonne Adegbenle, James Norton
Filed: 13 Aug 20
Utility
Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
11 Oct 22
Methods for the treatment of Alzheimer's disease psychosis, or a symptom thereof, comprising administering pimavanserin.
Bruce Duane Coate, James Randall Owen, Mark Donald Knowles, Srdjan R. Stankovic, James M. Youakim
Filed: 14 Dec 17
Utility
Formulations of pimavanserin
27 Sep 22
Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.
Ravindra Tejwani, Stephen Edward Abele, Emanuel Joseph Vizzotti
Filed: 14 Mar 22
Utility
Compounds, Salts Thereof and Methods for Treatment of Diseases
22 Sep 22
The present disclosure relates to compounds according to Formula (I), useful for treating diseases.
Ethan S. BURSTEIN, Roger OLSSON, Björn Gustav BORGSTRÖM, Karl Erik JANSSON, Niklas Patrik SKÖLD, Henrik VON WACHENFELDT, Larisa Yudina WAHLSTRÖM
Filed: 27 May 22
Utility
Pimavanserin for Treating Schizophrenia or for Treating Psychosis Secondary to Neurodegenerative Disorders or Depressive Disorder
15 Sep 22
The present disclosure relates generally to therapeutic use of pimavanserin or a pharmaceutical acceptable salt thereof.
Dragana Bugarski Kirola, Ethan S. Burstein
Filed: 22 Jul 20
Utility
Compounds, salts thereof and methods for treatment of diseases
13 Sep 22
The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.
Ethan S. Burstein, Roger Olsson, Karl Erik Jansson, Niklas Patrik Sköld, Larisa Yudina Wahlström, Björn Gustav Borgström, Henrik Von Wachenfeldt, Magnus Gustav Wilhelm Bergner
Filed: 20 Aug 18
Utility
Manufacturing Methods and Polymorphs of a Thiazoline Anti-hyperalgesic Agent
25 Aug 22
Provided herein are methods of making a thiazoline anti-hyperalgesic, Compound 1, and polymorphs thereof.
Scott L. Dax
Filed: 5 Oct 21
Utility
Selective Serotonin 2A/2C Receptor Inverse Agonists As Therapeutics for Neurodegenerative Diseases
4 Aug 22
Behavioral pharmacological data with the compound of formula (1), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias.
David M. Weiner, Robert E. Davis, Mark R. Brann, Carl-Magnus A. Andersson, Allan K. Uldam
Filed: 14 Sep 21
Utility
Formulations of Pimavanserin
23 Jun 22
Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.
Ravindra Tejwani, Stephen Edward Abele, Emanuel Joseph Vizzotti
Filed: 14 Mar 22
Utility
Methods of Treating Pain with a Thiazoline Anti-hyperalgesic
2 Jun 22
Methods of treating diabetic neuropathic pain and post-surgical pain are provided.
Scott L. Dax
Filed: 3 Nov 21
Utility
Compounds, salts thereof and methods for treatment of diseases
31 May 22
The present disclosure relates to compounds according to Formula (I), useful for treating diseases.
Ethan S. Burstein, Roger Olsson, Björn Gustav Borgström, Karl Erik Jansson, Niklas Patrik Sköld, Henrik Von Wachenfeldt, Larisa Yudina Wahlström
Filed: 21 Feb 20
Utility
Methods for Preparing N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE and Its Tartrate Salt and Polymorphic Form C
27 Jan 22
Marlon Carlos, Sagun Tandel, Roger Olsson, Mikael Hillgren, Matthew J. Fleming, Andreas Philipp Boudier, Beat T. Weber
Filed: 16 Mar 21
Utility
Methods of Treating Depression, Anxiety and Sexual Dysfunction Using the Compound Pimavanserin
20 Jan 22
The disclosure provides, in part, a method of treating anxious distress with major depressive disorder in a patient in need thereof, comprising administering to the patient N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof.
Ethan S. Burstein, Srdjan R. Stankovic, Bryan Dirks, Maurizio Fava, James Randall Owen, Daryl DeKarske
Filed: 30 Oct 19
Utility
5-HT2A Serotonin Receptor Inverse Agonists or Antagonists for Use In Reducing Amyloid-beta Peptides and Accumulation of Amyloid Plaques
6 Jan 22
Described are compounds and compositions for use in methods for reducing the rate of accumulation of amyloid plaques in a subject by administering a 5-HT2A serotonin receptor inverse agonist or antagonist, or pharmaceutically acceptable salts thereof.
Ethan S. Burstein
Filed: 16 Feb 21
Utility
Combination of pimavanserin and cytochrome P450 modulators
7 Dec 21
A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.
Andrew Parkinson
Filed: 15 Nov 19